Company intelligence / Profile preview

Chiral Biotech Pharma

Melbourne, Victoria, Australia

Ownership: Private
Development stage: Other

Overview

Chiral Biotech Pharma is an Australian biotechnology company focused on developing innovative therapies for mental health conditions. The company's lead program, Chir-110, is an oral capsule formulation of esketamine hydrochloride currently in Phase 1 clinical development. Chiral Biotech Pharma aims to improve the delivery and patient experience of esketamine, a known treatment for depression, through its proprietary oral formulation. The company is headquartered in Melbourne and collaborates with local clinical research organizations to advance its pipeline.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

CHIR-110

Unknown

Partnerships

iNGENu CRO

Beyond the preview

Go deeper on Chiral Biotech Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chiral Biotech Pharma.

Explore the full profile